Jazz Pharmaceuticals and AbCellera partner on T-cell antibody discovery

Jazz Pharmaceuticals and AbCellera announced a collaboration to discover next-generation T-cell engaging multispeci​fic antibodies, with Jazz paying $56 million upfront and eligible for up to $792 million in milestone payments per program. The partnership expands Jazz's oncology focus on gastrointestinal cancers while providing AbCellera meaningful upfront and milestone revenue.